Thermo Fisher Scientific Remaining performance obligations related to customer contracts that are unsatisfied or partially unsatisfied increased by 11.1% to $29.41B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 19.8%, from $24.54B to $29.41B. Over 3 years (FY 2020 to FY 2023), Remaining performance obligations related to customer contracts that are unsatisfied or partially unsatisfied shows an upward trend with a 28.1% CAGR.
other_revenue_remaining_performance_obligation| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $13.56B | $14.49B | $28.30B | $28.84B | $27.70B | $26.61B | $26.97B | $25.81B | $25.39B | $26.81B | $26.92B | $26.37B | $25.93B | $25.30B | $24.54B | $25.04B | $26.46B | $29.41B |
| QoQ Change | — | +6.9% | +95.3% | +1.9% | -4.0% | -3.9% | +1.4% | -4.3% | -1.6% | +5.6% | +0.4% | -2.0% | -1.7% | -2.4% | -3.0% | +2.0% | +5.7% | +11.1% |
| YoY Change | — | — | — | — | +104.3% | +83.6% | -4.7% | -10.5% | -8.3% | +0.8% | -0.2% | +2.2% | +2.1% | -5.6% | -6.9% | -3.4% | +4.6% | +19.8% |